Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2

World Journal of Gastroenterology

Volumn 14, Issue 16, 2008, Pages 2494-2500

  Zhang, Bo ^a   Wang, Chang Liang ^a   Zhao, Wen Hua ^a   Lv, Ming ^b   Wang, Chun Ying ^a   Zhong, Wei Xia ^a   Zhou, Wu Yuan ^a   Yu, Wen Sheng ^a   Zhang, Yan ^c   Li, Sheng ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b ZIBO CENTRAL HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

5 lipoxygenase pancreatic tumor cyclooxygenase2; Carcinoma in nude mice; DHDMBF30

Indexed keywords

ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FURAN DERIVATIVE; LIPOXYGENASE INHIBITOR; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 47849093031     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2494     Document Type: Article

References (30)

1. Bommareddy A, Arasada BL, Mathees DP, Dwivedi C. Chemopreventive effects of dietary flaxseed on colon tumor development. Nutr Cancer 2006; 54: 216-222
2. Yoshikawa R, Fujiwara Y, Koishi K, Kojima S, Matsumoto T, Yanagi H, Yamamura T, Hashimoto-Tamaoki T, Nishigami T, Tsujimura T. Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence. World J Gastroenterol 2007; 13: 2283-2288
3. Ferrera P, Arias C. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells. Neurochem Int 2005; 47: 589-596
4. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, Schiavone N, Messerini L, Vannacci A, Capaccioli S, Perna F, Lulli M, Fabbroni V, Perigli G, Bechi P, Masini E. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 2006; 5: 2716-2726
5. Zhang B, Shi XT, Yi LH, Li ZY, Yu JM. Expression of 5-lipoxygenase in pancreatic cancer and its clinical significance. Zhonghua Zhongliu Fangzhi Zazhi 2004; 11: 68-70
6. Gregor JI, Kilian M, Heukamp I, Kiewert C, Kristiansen G, Schimke I, Walz MK, Jacobi CA, Wenger FA. Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 89-97
7. Schroeder CP, Yang P, Newman RA, Lotan R. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol 2007; 6: 183-192
8. Yang K, Ma W, Liang H, Ouyang Q, Tang C, Lai L. Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol 2007; 3: e55
9. Sun Z, Sood S, Li N, Ramji D, Yang P, Newman RA, Yang CS, Chen X. Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. Carcinogenesis 2006; 27: 1902-1908
10. Luo M, Lee S, Brock TG. Leukotriene synthesis by epithelial cells. Histol Histopathol 2003; 18: 587-595
11. Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, Gomez-Gerique JA, Tunon J, Egido J. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 2007; 320: 108-116
12. Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z. The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003; 106: 327-3233
13. de Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol Sci 2003; 24: 245-252
14. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003; 62: 501-509
15. Park S, Han SU, Lee KM, Park KH, Cho SW, Hahm KB. 5-LOX inhibitor modulates the inflammatory responses provoked by Helicobacter pylori infection. Helicobacter 2007; 12: 49-58
16. Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, Ichikawa W, Nihei Z, Sugihara K. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876-1881
17. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, Lee FY, Lee SD. Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis. Clin Sci (Lond) 2007; 112: 533-542
18. Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology 2007; 79: 34-41
19. Kim JS, Kim JC, Shim SH, Lee EJ, Jin W, Bae K, Son KH, Kim HP, Kang SS, Chang HW. Chemical constituents of the root of Dystaenia takeshimana and their anti-inflammatory activity. Arch Pharm Res 2006; 29: 617-623
20. Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, Wu LI, Gan L, Chen J, Kellstein DE, Green SA, Tulich JL, Rosario-Jansen T, Magrisso IJ, Wehmeyer KR, Kuhlenbeck DL, Eichhold TH, Dobson RL. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position. J Med Chem 1998; 41: 3515-3529
21. Zheng M, Zhang Z, Zhu W, Liu H, Luo X, Chen K, Jiang H. Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues. Bioorg Med Chem 2006; 14: 3428-3437
22. Danz H, Stoyanova S, Thomet OA, Simon HU, Dannhardt G, Ulbrich H, Hamburger M. Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis. Planta Med 2002; 68: 875-880
23. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-1621
24. Nieves D, Moreno JJ. Effect of arachidonic and eicosapentaenoic acid metabolism on RAW 264.7 macrophage proliferation. J Cell Physiol 2006; 208: 428-434
25. Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498-506
26. Pommery J, Pommery N, Henichart JP. Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 411-417
27. Huang RH, Chai J, Tarnawski AS. Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J Gastroenterol 2006; 12: 6446-6452
28. Fiorucci S, Distrutti E, de Lima OM, Romano M, Mencarelli A, Barbanti M, Palazzini E, Morelli A, Wallace JL. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003; 17: 1171-1173
29. Ding XZ, Tong WG, Adrian TE. Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology 2001; 1: 291-299
30. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in antiinflammatory therapy? Biochem Pharmacol 2001; 62: 1433-1438